All In Biotech

Drug Trial Radar · NCT06864169

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Aug 18, 2026

Study completion Jan 4, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).

Conditions

  • Gastrointestinal Cancer

Interventions

  • Raludotatug Deruxtecan (R-DXd)Biological

    Administered via intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Approximately 15 months

Locations

41 sites in 10 countries. Site status is shown where the registry gives one.

  • Yale New Haven Hospital ( Site 0375)

    New Haven, Connecticut

  • Sibley Memorial Hospital ( Site 0372)

    Washington D.C., District of Columbia

  • Mt Sinai Comprehensive Cancer Center ( Site 0345)

    Miami Beach, Florida

  • St. Vincent Healthcare Frontier Cancer Center ( Site 0347)

    Billings, Montana

  • Morristown Medical Center ( Site 0349)

    Morristown, New Jersey

  • University Hospitals Cleveland Medical Center ( Site 0369)

    Cleveland, Ohio

  • University of Virginia Cancer Center ( Site 0365)

    Charlottesville, Virginia

  • University of Wisconsin Carbone Cancer Center ( Site 0348)

    Madison, Wisconsin

  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006)

    La Rioja, Argentina

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0001)

    Mar del Plata, Buenos Aires, Argentina

  • Nefra Medical Care - CEMIC Saavedra ( Site 0008)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos ( Site 0007)

    Rosario, Santa Fe Province, Argentina

  • Sunnybrook Research Institute ( Site 0044)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 0041)

    Toronto, Ontario, Canada

  • Centre Hospitalier de l'Université de Montréal ( Site 0042)

    Montreal, Quebec, Canada

  • FALP ( Site 0062)

    Santiago, Region M. de Santiago, Chile

  • Centro de Estudios Clínicos SAGA ( Site 0064)

    Santiago, Region M. de Santiago, Chile

  • Clínica UC San Carlos de Apoquindo ( Site 0066)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0069)

    Santiago, Region M. de Santiago, Chile

  • Pitie Salpetriere University Hospital ( Site 0082)

    Paris, France

  • Centre François Baclesse ( Site 0085)

    Caen, Calvados, France

  • Institut Regional du Cancer Montpellier ( Site 0084)

    Montpellier, Herault, France

  • Gustave Roussy ( Site 0081)

    Villejuif, Val-de-Marne, France

  • Prince of Wales Hospital ( Site 0122)

    Hksar, Hong Kong

  • Queen Mary Hospital ( Site 0121)

    Hksar, Hong Kong

  • Hospital Clinic de Barcelona ( Site 0223)

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón ( Site 0225)

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz ( Site 0224)

    Madrid, Spain

  • Institut Català d'Oncologia (ICO) - Badalona ( Site 0222)

    Badalona, Barcelona, Spain

  • Hospital Universitario Marqués de Valdecilla ( Site 0221)

    Santander, Cantabria, Spain

  • Universitaetsspital Zuerich ( Site 0242)

    Zurich, Switzerland

  • Universitaetsspital Basel ( Site 0241)

    Basel, Canton of Basel-City, Switzerland

  • Hôpitaux Universitaires de Genève (HUG) ( Site 0245)

    Geneva, Canton of Geneva, Switzerland

  • China Medical University Hospital ( Site 0267)

    Taichung, Taiwan

  • Taichung Veterans General Hospital ( Site 0265)

    Taichung, Taiwan

  • National Cheng Kung University Hospital ( Site 0263)

    Tainan, Taiwan

  • National Taiwan University Hospital ( Site 0261)

    Taipei, Taiwan

  • Mackay Memorial Hospital ( Site 0266)

    Taipei, Taiwan

  • Taipei Veterans General Hospital ( Site 0262)

    Taipei, Taiwan

  • Ramathibodi Hospital. ( Site 0282)

    Bangkok, Bangkok, Thailand

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.